Project 1 Abstract Black women suffer higher incidence of poor-prognosis breast cancer subtypes and worse stage-specific mortality. Our previous Carolina Breast Cancer Study(CBCS)-based SPORE discoveries have integrated population-based epidemiology with tumor biology to demonstrate that young black women are more likely to develop Basal-like tumors. More recently, we found that black women also have higher frequency of Luminal B and HER2-enriched breast tumors. Furthermore, even among the best-prognosis clinical subset of estrogen receptor (ER)-positive/HER2-negative cancers, black women have higher risk of recurrence (ROR) scores. These findings implicate tumor biology as a key contributor to racial mortality disparities. Some tumor factors (i.e., higher frequency of HER2-enriched subtype) may be targetable, illustrating how population-based genomics can advance precision medicine. In this Project, we propose to deepen our understanding of racial differences in tumor biology, etiology and progression, with a focus on tumor mutational signatures and immune responses. The frequency of specific mutations (i.e. TP53, PIK3CA), and the overall patterns of somatic mutations (mutational signatures) can be informative about the underlying biological processes that have gone awry from the earliest stages of carcinogenesis. In addition, new discoveries have emphasized the importance of the immune system in breast cancer etiology and progression. With our rich resource of tumor biospecimens (exceptional 96% tumor procurement from 3000 cases), we will sequence tumor DNA and identify mutational signatures in black and white women (Aim 1) and we will characterize tumor immune microenvironments using six immunohistochemical markers and RNA profiling for 50 genes (Aim 2). While The Cancer Genome Atlas (TCGA) has evaluated racial differences in tumors with hundreds of thousands of data points per patient, limitations included small numbers of black participants (CBCS is ten-fold larger than TCGA), a sampling scheme that was not population-based, and lack of detailed covariate and follow-up data. TCGA advances have allowed us to increase sequencing efficiency for population-based work and have helped in developing an efficient RNA panel for immune profiling, resulting in a plan for cost-effective collection of mutational signatures and expression profiles in 2000 women (1000 black, 1000 white, sampling from the entirety of CBCS). Utilizing these advances in the context of the CBCS, we hypothesize that mutational signatures and immune responses are differentially associated with race, age, and breast cancer subtype. We also expect to identify some mutational signatures that vary as a function of immune profiles. The tumor biological variables collected in Aims 1 and 2 will be assessed as predictors of breast cancer recurrence and survival. In addition, impact of tumor biology may be confounded by other patient-level factors such as socioeconomic status, access to care, treatment delay and treatment adherence. Multivariable modeling (Aim 3) will identify the relative strengths of tumor biology and patient-level features that contribute to survival, thus allowing for impactful precision medicine strategies. 1

Public Health Relevance

Racial differences in the mutational profiles and immune signatures profiles may contribute to mortality disparities. This proposal will evaluate mutational signatures using DNA sequencing and will characterize immune profiles to identify factors contributing to differences in breast cancer outcomes between black and white women. Finally, tumor and microenvironment biology will be considered in association with recurrence and survival, while simultaneously addressing access to care, treatment, and adherence. This integration of biology and access will lead to new discoveries relevant to precision management of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-24A1
Application #
9487498
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304

Showing the most recent 10 out of 598 publications